Diagnosis of Charcot-Marie-Tooth Disease by Banchs, Isabel et al.
Hindawi Publishing Corporation
Journal of Biomedicine and Biotechnology
Volume 2009, Article ID 985415, 10 pages
doi:10.1155/2009/985415
Review Article
Diagnosis of Charcot-Marie-Tooth Disease
Isabel Banchs,1 Carlos Casasnovas,2 Antonia Albert´ ı,2 Laura De Jorge,1 M´ onica Povedano,2
Jordi Montero,2 JuanAntonioMart´ ınez-Matos,2 andVictor Volpini1
1Molecular Diagnosis Center of Inherited Diseases, Institut de Investigaci´ o Biom` edica de Bellvitge (IDIBELL), Gran Via 199,
08907 L’Hospitalet de Llobregat, Barcelona, Spain
2Unitat de Neuromuscular, Neurology Department, Hospital Universitari de Bellvitge-IDIBELL, Feixa Llarga s/n,
08907 L’Hospitalet de Llobregat, Barcelona, Spain
Correspondence should be addressed to Carlos Casasnovas, carloscasasnovas@bellvitgehospital.cat
Received 24 March 2009; Revised 24 June 2009; Accepted 8 July 2009
Recommended by John McGregor
Charcot-Marie-Tooth (CMT) disease or hereditary motor and sensory neuropathy (HMSN) is a genetically heterogeneous group
of conditions that aﬀect the peripheral nervous system. The disease is characterized by degeneration or abnormal development
of peripheral nerves and exhibits a range of patterns of genetic transmission. In the majority of cases, CMT ﬁrst appears in
infancy, and its manifestations include clumsiness of gait, predominantly distal muscular atrophy of the limbs, and deformity
of the feet in the form of foot drop. It can be classiﬁed according to the pattern of transmission (autosomal dominant, autosomal
recessive, or X linked), according to electrophysiological ﬁndings (demyelinating or axonal), or according to the causative mutant
gene. The classiﬁcation of CMT is complex and undergoes constant revision as new genes and mutations are discovered. In this
paper, we review the most eﬃcient diagnostic algorithms for the molecular diagnosis of CMT, which are based on clinical and
electrophysiological data.
Copyright © 2009 Isabel Banchs et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Hereditary neuropathies are a genetically heterogeneous
group of diseases that aﬀect the peripheral nervous system.
The most common form is the hereditary motor and
sensory neuropathy (HMSN), also called Charcot-Marie-
Tooth disease (CMT). Almost 120 years have elapsed since
the ﬁrst contemporary description of the same familial neu-
rological syndrome, “peroneal muscular atrophy” (Charcot
and Marie, 1886; Tooth, 1886). Dyck and Lambert (1968)
were the ﬁrst to observe, using electrophysiological studies, a
marked nerve conduction slowing in some families, whereas
conduction was preserved in others. These authors con-
tributed to a rational classiﬁcation of the complex peroneal
muscular atrophies according to inheritance pattern and
clinical, electrophysiological, and pathological features. They
introduced the term “hereditary motor and sensory neu-
ropathy” and classiﬁed the autosomal-dominant form with
low conduction velocities as HMSN type I (or CMT 1) and
the autosomal-dominant form with preserved conduction
velocities as HMSN type II (or CMT 2). Harding and
Thomas (1980) observed that the motor nerve conduction
velocities (NCV) showed a bimodal distribution and set
a median NCV of 38m/s as an arbitrary but rational
threshold between the demyelinating HMSN type I (motor
NCV <38m/s) and the axonal HMSN type II (motor NCV
>38m/s).
2. Classiﬁcation
The most commonly used classiﬁcation combines clinical
ﬁndings with the inheritance pattern (autosomal domi-
nant, autosomal recessive, or X linked) and either electro-
physiological or anatomical pathology ﬁndings (axonal or
demyelinating). The demyelinating forms are characterized
by predominantly aﬀecting the sheath of myelin that sur-
rounds the axon of peripheral nerves. The main function
of myelin is to increase NCV. Therefore, the most notable
electrophysiological ﬁnding in this form of the disorder is
a low NCV. The axonal forms of the disease are caused by
speciﬁc eﬀects on the axon itself; neurophysiological studies
reveal conserved NCVs, while the amplitude of the motor
and sensory potentials (which are a reliable indication of
axon conservation) are greatly reduced. Recently, disease2 Journal of Biomedicine and Biotechnology
Figure 1: Foot drop in a patient with CMT1 caused by duplication
of the genomic fragment that encompasses PMP22 (CMT1A).
variantshavebeendescribedthatcombineeﬀectsonboththe
myelin and the axon and that, therefore, have intermediate
conduction speeds. The transmission of many of these new
variants is X linked [1].
Thecombinationofthesedataallowstheidentiﬁcationof
several main categories of CMT. The majority of cases can be
classiﬁed as CMT1 (i.e., demyelinating forms with low NCVs
and autosomal-dominant transmission), CMT2 (i.e., axonal
form, usually showing a dominant inheritance pattern), or
CMT4 (i.e., recessive and severe forms). Each of these types
can be further divided into subtypes, depending on the
underlying causative molecular defect (Table 1). However,
it should be noted that there is not a good genotype—
phenotype correlation and that great variability exists, both
within and between families, regarding the degree of clinical
expression [2]. With the advent of genetic testing, nerve
biopsies are reserved for patients for whom genetic testing
did notleadtoa moleculardiagnosis, forpatients withatypi-
calpresentation,orforpatientswithsuspectedinﬂammatory
neuropathy. Recently, peripheral nerve, magnetic resonance
studies and skin biopsy have emerged as potential diagnostic
aids for certain types of hereditary neuropathies [3].
3. Epidemiology of CMT
The prevalence of CMT ranges from 10 to 30 per 100,000,
depending on the geographical region of origin [4, 5]. Two
extensive studies in the literature indicate that the most com-
mon subtypes are CMT1 (demyelinating with autosomal-
dominant transmission) and CMT2 (axonal and usually
dominant). In Western countries, the most common cause
of CMT1 is CMT1A, which results from the duplication
of a genomic fragment that encompasses the PMP22 gene
on chromosome 17. It would appear that CMT1B is more
common in Japan than in Western countries [6, 7]. In the
recent years, all the published studies identify CMT2A as the
mostcommoncauseofCMT2(whichwouldaccountfor10–
33% of cases) [8].
4. CMT1
This form is characterized by autosomal-dominant trans-
mission and NCVs in the demyelinating range, as indicated
by electrophysiological studies, that is, NCVs <38m/s (the
normal NCV being >50m/s). The degree of reduction in
NCV does not correlate with the clinical severity of the
disease,andlowNCVscanevenbedetectedinasymptomatic
individuals and as early as one year of age [9].
Nerve biopsy, which is not routinely carried out, reveals
a loss of large myelinated ﬁbers, demyelination and remyeli-
nation, and an “onion bulb” appearance.
CMT1 can be divided into CMT1 A, B, C, D, E, or
F, depending on the underlying causative molecular defect
(Table 1).
4.1. CMT1A. CMT1A is the most common cause of CMT1
in Western countries. In the majority of cases, it is caused
by the duplication of a 1.5Mb fragment on chromosome
17p.11 that includes the PMP22 gene. The PMP22 protein is
predominantly expressed in Schwann cells and can be found
in compactmyelin. Ithas a structuralfunction (myelination)
and regulates cell growth. Overexpression of PMP22 reduces
the proliferation of Schwann cells. This trait is dominant; in
89% of cases, it is of paternal origin, while in 11% of cases it
is of maternal origin [2, 9]. It is stimated that about 5–24%
of the the duplication mutation may ocurr de novo thus, the
absence of family history does not preclude genetic testing.
Molecular studies of PMP22 are carried out using
multiplex ligation-dependent probe ampliﬁcation (MLPA),
in which all 38 fragments of the gene are ampliﬁed at once
(nine within the diﬀerent exons of the PMP22 gene, seven
in the region that encompasses the duplication, two outside
theduplicatedregion,andtherestindiﬀerentchromosomes,
as controls to calculate gene dosage). Once this Polimerase
Chain Reaction has been performed, sequence analysis is
carried out using an ABI Prism sequencer. To complete the
study, seven molecular markers or microsatellites present in
the 1.5Mb duplicated region are analyzed. Microsatellites
are repetitions of 2 to 6 nucleotides that exhibit great
variability, which renders them very polymorphic. They
are normally found in noncoding regions of the genome.
The microsatellites considered here are D17S839, D17S921,
D17S1356, D17S1357, D17S1358, D17S955, and D17S261.
They are ampliﬁed using PCR and are then analyzed using
the ABI Prism sequencer.
Point mutations of this gene have also been described as
a cause of CMT1A, although not very frequently (2–5% of
CMT1A cases) [7]. It is estimated that about one third of the
point mutations may ocurr de novo. The molecular analysis
of these cases should be performed by direct sequencing of
each of the coding fragments and exons of the gene.
Symptoms usually ﬁrst appear in infancy and include
clumsinessofgaitanddeformityofthefeet.Patientsmaysuf-
ferfromcramps,whichareheightenedafterphysicalexercise.
Positive sensory alterations are extremely rare and represent
a departure feature from acquired polyneuropathies. Foot
drop is evident on physical examination (Figure 1)a n ds o
are retraction of the Achilles tendon and the presence ofJournal of Biomedicine and Biotechnology 3
Table 1: Summary of CMT classiﬁcation, including clinical data (such as electrophysiological results) and molecular ﬁndings.
Dominant forms
CMT 1 (demyelinating)
Type Gene Inheritance Locus
CMT1A: PMP-22 Dominant/sporadic 17p11
CMT1B: P0 protein Dominant 1q22
CMT1C: LITAF Dominant 16p13
CMT1D: EGR2 Dominant 10q21
CMT1E: P0 protein Dominant 1q22
CMT1F: Neuroﬁlament Dominant/sporadic 8p21
Light chain
CMT 2 (axonal)
Type Gene Inheritance Locus
CMT 2A1: KIF1B Dominant 1p36
CMT 2A2: MFN2 Dominant 1p36
CMT 2B: RAB7 Dominant 3q13-q22
CMT 2C: Dominant 12q23-q24
CMT 2D: GARS Dominant 7p15
CMT 2E: Neuroﬁlament light chain Dominant 8p21
CMT 2F: HSPB1 Dominant/recessive 7q11-q21
CMT 2G: Dominant 12q12
CMT 2I: P0 Dominant 1q22
CMT 2J: P0 Dominant 1q22
CMT 2L: HSPB8 Dominant 12q24
AR-CMT2A Lamin A/C Recessive 1q21.2
AR-CMT2B Med25 Recessive 19q13.3
CMT 2K: GDAP1 Recessive/dominant 8q21
Intermediate NCV
Type Gene Inheritance Locus
Connexin-32 GJB1 X-linked Xq13
CMT DIA Dominant 10q24
CMT DIB DNM2 Dominant 19p12
CMT DIC Tyrosyl-tRNA synthetase Dominant 1p34
CMT DI3 P0 Dominant 1q22
CMT 2E: Neuroﬁlament light chain Dominant 8p21
CMT 4
Type Gene Inheritance Locus
CMT 4A: GDAP1 Recessive 8q21
CMT 4B1: MTMR2 Recessive 11q23
CMT 4B2: SBF2 Recessive 11p15
CMT 4C: SH3TC2 (KIAA1985) Recessive 5q32
CMT 4D (Lom): NDRG1 Recessive 8q24
CMT 4E: EGR2 Recessive/dominant 10q21
CMT 4F: Periaxin Recessive 19q13
HMSN-Russe (4G) Recessive 10q23
CMT 4H: FGD4 Recessive 12q124 Journal of Biomedicine and Biotechnology
an abundance of corns. Over time, these symptoms are
compounded by weakness and atrophy of the intrinsic foot
and peroneal muscles, which cause “steppage” gait. The
hands can also be aﬀected, with the presence of claw hand
in extreme cases. Generalized areﬂexia is an early and very
frequent ﬁnding. Some patients present with scoliosis (10%)
and nerve hypertrophy (25–66%). Extensive electrophysio-
logical studies reported in the literature reveal that NCVs
are always in the demyelinating range and remain constant
throughout the evolution of the disease. This conﬁrms that
the determination of motor NCV of the median nerve is
an excellent marker for genetically determined neuropathies.
C o n d u c t i o nb l o c k sa r er a r ei nC M T 1 A ,a sa r et e m p o r a l
dispersion phenomena, as opposed to what is observed in
acquired demyelinating neuropathies or CMT1 Types B and
C. There may also be signs of secondary axonal degeneration
[7].
Hereditary Neuropathy with Liability to Pressure Palsies
(HNPP).
In the majority of cases (85%), HNPP is caused by the
deletionofa1.5Mbfragmentonchromosome17p.11,which
includes the PMP22 gene. Therefore, the deleted region is
identical to the region duplicated in CMT1A. Nonsense
mutations, frameshifts with premature termination, mis-
sense mutations, and splice site changes have been reported
in the remaining 15% of cases. The clinical phenotype of
thesepatientsischaracterizedbyrecurrentnervedysfunction
at compression sites. Asymmetric palsies can occur after
relatively minor compression or trauma. With ageing, these
patients can have a signiﬁcant clinical overlap with CMT1, as
the repeated injuries to the nerve can prevent full reversal.
Electrophysiological ﬁndings include mildly slowed NCV
and increased motor latencies and conduction blocks [3, 10–
12].
4.2.CMT1B. This formof thedisease iscausedby mutations
in the myelin zero protein (MZP), which is a 28kDa protein
comprising 219 amino acids. MZP is found exclusively in
Schwanncellsandisthemostabundantproteininthemyelin
of peripheral nerve tissues, whereas it is not found in the
myelin of the central nervous system. It is indispensable for
the normal structure and function of myelin. The gene that
encodes MZP has six exons and is located on chromosome
1q22. In the majority of cases, the disease is caused by point
mutations, particularly in exons 2 and 3, which correspond
to the immunoglobulin-like extracellular domain [8–10].
In CMT1B, the onset of symptoms may be delayed,
movement of the pupils may be aﬀected, and deafness may
be present. Electrophysiological studies reveal that patients
can be segregated into two groups, according to NCV: one
with NCVs <38m/s and the other with NCVs above this
threshold (i.e., in the axonal range). These ﬁndings render
the classiﬁcation of CMT even more diﬃcult, as mutations
in the same gene can cause either CMT1 (demyelinating),
CMT2 (axonal), CMT with intermediate NCV (CMTDI3)
or CMT associated with deafness (CMT1E) [6]. Nerve
conduction blocks have also been described in CMT1B
[13].
4.3. Other Types of CMT1. Mutations in the LITAF and
ERG2 genes cause CMT1C and D, respectively. In CMT1C,
electrophysiological ﬁndings include the presence of tempo-
ral dispersion and nerve conduction blocks. The molecular
study of both genes is carried out by direct sequencing to
search for point mutations in coding regions [6].
5.DiagnosticProtocol for CMT1
The diagnostic protocol for demyelinating and dominant
CMT (CMT1), which has been adapted from England et
al. [14, 15], is summarized in Figure 2. Given that the data
available suggest that duplication of PMP22 is the most
frequent cause of CMT1 and that mutation of PMP22 is
the most common cause of sporadic CMT1 [6, 16], it
is proposed that the study of demyelinating CMT should
begin by checking for duplication of the genomic fragment
encompassing PMP22. Once this duplication has been ruled
out, in sporadic cases or in cases where there is no male-
to-male transmission, researchers should check for point
mutations in the GJB1 gene (which can be used to diagnose
up to 12% of cases). If there are no changes in GJB1, MPZ
and then PMP22 should be analyzed for the presence of
point mutations. In the remaining cases, one should look for
alterations in genes that are known to cause CMT at a lower
frequency: EGR2, NEFL,a n dLITAF.
6. CMT2
T h em o s tc o m m o nf o r mo fC M T 2i sC M T 2 A[ 17–19].
It is caused by mutations in MFN2,w h i c hc o d e sf o r
the mitofusin 2 protein. Mitofusin 2 is a GTPase that is
involved in the fusion of mitochondria. It is ubiquitously
expressedandispresentinthespinalcord,muscle,heart,and
peripheral nerves. Intracellularly, it is attached to the outer
mitochondrial membrane via its C-terminal domain. It also
has an N-terminal GTPase domain, which is located in the
cytoplasm. This domain can form a complex with another
mitochondrialprotein,mitofusin1.Mitofusin2regulatesthe
architecture of the mitochondrial network via mitochondrial
fusion, in a stage downstream of mitofusin 1 [19–24].
The majority of MFN2 mutations described in the
literature are of the missense type, although stop mutations
have also been described. These mutations have been found
in cytoplasmic domains, within or immediately upstream of
the GTPase domain, within two coiled-coil domains, or in
association with the functioning or mitochondrial targeting
of mitofusin 2. De novo mutations have also been found
occasionally. Although most cases are autosomal dominant,
homozygous or compound heterozygous mutations that
produce a more severe form of the disease have been
described. The molecular study of CMT2 is carried out by
direct sequencing of the 19 exons of MFN2 [18–20].
The CMT2 phenotype is highly heterogeneous, with
variable penetrance, and there are mutations associated
with both early- and late-onset forms of the disease. Some
frequent clinical associations have been described, such as
the presence of optical atrophy and tremors, migraine, andJournal of Biomedicine and Biotechnology 5
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Figure 2: Diagnostic protocol for demyelinating CMT (adapted from England et al.) [10, 11].
eﬀects on the central nervous system. In general, we expect
toﬁndgreateratrophyofthelimbs(Figure 3)andanabsence
of nerve hypertrophy on palpation [23, 25].
O t h e rl e s sc o m m o nC M T 2s u b t y p e sw i t hu n u s u a l
characteristics may be encountered. CMT2B presents with
ulcerative-mutilating phenomena, CMT2C exhibits paralysis
of the vocal chords and aﬀects the diaphragm, CMT2D has
ag r e a t e re ﬀect on the intrinsic muscles of the hand, and
CMT2J is associated with hearing impairment, alterations of
the pupils, and severe sensory disruption. Subtypes 2I and
2J are caused by mutations in the MPZ gene and exhibit
conserved NCVs; that is, in the axonal range. Therefore,
defects in the production of MPZ can lead to both Type 1
andType2CMT.CasesofCMTcausedbymutationsinMPZ
that result in NCVs in the intermediate range have also been
reported [8, 9, 16].
The majority of cases of CMT2 show an autosomal-
dominant inheritance pattern. However, some of the CMT26 Journal of Biomedicine and Biotechnology
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Figure 4: Diagnostic protocol for axonal CMT; adapted from England JD et al. [10, 11].Journal of Biomedicine and Biotechnology 7
causative genes display recessive inheritance (RAB7 and
LMNA,amongothers),butthesearelimitedtoafewfamilies.
An initial electrophysiological study is necessary to
distinguish CMT2 from CMT1.
NCVs are normal in CMT2, but the amplitudes of the
motor and sensory potentials are severely reduced. It diﬀers
fromdistalspinalmuscularatrophyinthatthelatterpresents
normal sensory neurography. The anatomical pathology
points to axonal degeneration with relative preservation of
myelin.
7.DiagnosticProtocol for CMT2
It is proposed to start the study of axonal CMT by
checking for point mutations of MFN2 (Figure 4,a d a p t e d
from England et al. [14, 15]). This is probably the most
common cause of CMT2 and is responsible for up to 33%
of cases in families where the inheritance pattern is known
to be dominant. The data currently available suggest that
variations in the GJB1 gene may explain up to 12% of CMT
(both axonal and demyelinating). Hence, the presence of
mutations in this gene should be ruled out in cases of axonal
CMT that have no evidence of mutations in MFN2 and that
are sporadic or have no known male-to-male transmission.
After this, and in selected cases, the study should continue by
checking for mutations in the genes that code for MPZ and
NEFL (if dominant) or for GDAP1 (if sporadic or recessive).
Other genes that could be studied in selected cases are RAB7,
GARS, and HSPB1 [13, 24–31].
8. CMT4
CMT4A is the most common form of CMT4 and is
caused by mutations in the GDAP1 gene. It is a severe
motor and sensory neuropathy with early onset (Figure 5).
Neurophysiological studies reveal NCVs in both the axonal
and demyelinating range. CMT4A can be associated with
paresis of the vocal cords [32, 33].
CMT4B1iscausedbymutationsinthegeneencodingthe
myotubularin-related protein 2 (MTMR2). Disease onset is
in early infancy. Facial, bulbar, and diaphragmatic involve-
ment has been reported in some families [34–37].
The CMT4B2 locus was mapped to chromosome 11p15
in Tunisian families [38].
CMT4C was mapped to chromosome 5q23-q33 [39]a n d
wasrecentlyassociatedwithmutationsintheKIAA1985gene
[40]. The hallmark of CMT4C is the presence of early and
severescoliosis, whichis reportedly the presenting sign in the
majority of patients [41].
Recessive CMT caused by mutations in NDRG1 is
particularly common among the Gypsy population. This
form is classiﬁed as CMT4D (or Type “Lom”; Lom is the
region of Bulgaria where this mutation originated). In our
diagnostic protocol (Figure 6), we suggest studying this gene
ﬁrst if the subject is of Gypsy ethnicity; if no mutation is
found or the subject is from a diﬀerent ethnic group, then
GDAP1 s h o u l db ea n a l y z e d[ 14, 15]. The other CMT related
to the Gypsy population is the CMT Russe type. This entity
has been described in Bulgarian, Romanian, and Spanish
Gypsies [42, 43] and was mapped to chromosome 10q23.
It is characterized by an age of onset ranging between 8 to
16 years and progression to severe distal weakness. NCVs are
moderately reduced [41].
CMT4E and CMT4F are associated with mutations in
the EGR2 and periaxin (PRX) genes, respectively. Finally,
CMT4H was recently mapped to a new locus on chromo-
some 12p11.21-q13.11 [44]( Table 1).
9. CMT with IntermediateNCV
DI-CMT Type A has been mapped to chromosome 10q24.1-
q25.1 in an Italian family. It has dominant inheritance, and
the age of onset is in the ﬁrst or second decade of life.
It is characterized by distal weakness, mild sensory loss,
absent tendon reﬂexes, and slow progression. Many of these
patients never use a wheelchair. Nerve conduction studies
reveal NCVs ranging between 25 and 45m/s (i.e., in the
intermediate range). Loss of large myelinated axons and
occasional onion bulbs are found in nerve biopsies.
DI-CMT Type B is related to mutations in the dynamin 2
(DNM2) gene located on chromosome 19p12-p13.2. Domi-
nantinheritanceofthetraithasbeendescribedinAustralian,
Belgian, and North-American families. This disease is allelic
with centronuclear myopathy. The clinical onset of disease
occurs in the ﬁrst or second decade of life, and patients
present with a slow evolution. Electrodiagnostic studies
reveal NCVs in the intermediate range (24–54m/s).
DI-CMT Type C is associated with mutations in the
tyrosyl-tRNAsynthetase(YARS)geneonchromosome1p34-
p35. Two DI-CMT Type C families have been reported, one
from Midwestern USA and one from Bulgaria. Because of
slow disease progression over decades, many patients never
use a wheelchair. Electrodiagnostic studies revealed NCVs in
the intermediate range (30–50m/s). Other CMT disorders
with intermediate NCV have been reported in association
with mutations in MPZ (CMT-DI3), in the neuroﬁlament
light chain protein (NEFL)g e n e ,a n di nGJB-1 (CMT X) [3].
10. CMTX
The most common form of CMTX is dominant, X linked,
and caused by point mutations in the GJB1 gene, which is
located in chromosome Xq13.1. Many diﬀerent mutations
have been described that are normally located on the cell
surface domains of the protein (i.e., extracellular domains).
At present, mutation of GJB1 is the second most common
cause of CMT in our setting [6, 7, 27, 45–49]. GJB1 encodes
c o n n e x i n3 2 ,w h i c ha c t sa sag a pj u n c t i o na tt h el e v e lo f
compact myelin.
Boys experience symptoms in the ﬁrst decade of life and
are seriously aﬀected. In women, the disease follows a less
severe course, with onset at 20–30 years of age and a mild
presentation of the disease.
The slowing of nerve conduction is proportional to
clinical severity. Unlike CMT1, there are more myelinated
ﬁbers, more regenerating ﬁbers, and fewer “onion bulbs”, as
assessed by anatomical pathology.
Characteristically, electrophysiological studies reveal
NCVs in the intermediate range; that is, between the8 Journal of Biomedicine and Biotechnology
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Figure 6: Diagnostic protocol of CMT with a suspected recessive inheritance pattern (adapted from England et al.) [10, 11].
demyelinating range of CMT1 and the axonal range of
CMT2.
Although rare, there are two recessive X-linked forms of
CMT,whichareassociatedwithdeafness,mentalretardation,
and encephalomyelitis [48, 50].
11. Evolution and Treatment of CMT
The disease follows a slow but progressive course. At present,
there is no etiological treatment; however, a prospective
European multicentre study is under way to assess the use of
highdosesofascorbicacidinpatientswithCMT1A.Ascorbic
acid has been associated with improved clinical evolution in
mice. It is particularly important that patients with CMT
avoid other known risk factors for the development of
neuropathies, such as the use of neurotoxins (e.g., drugs
and alcohol). The literature describes transitory clinical
improvementsinCMT1Baftertreatmentwithcorticoids[4].
12. Conclusions
CMT is a disease that is highly heterogeneous, both clinically
and genetically. Clinical and electrophysiological data are
indispensable for performing eﬃcient molecular diagnosesJournal of Biomedicine and Biotechnology 9
of this entity. It is crucial to know which subtype aﬀects each
patient in order to provide good clinical treatment, eﬀective
diagnosis of family members, and valid prognosis.
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